Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
Japanese patients
adjuvant drug therapy
ipilimumab
melanoma
nivolumab
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
09
04
2019
accepted:
05
09
2019
pubmed:
23
10
2019
medline:
14
4
2020
entrez:
23
10
2019
Statut:
ppublish
Résumé
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.
Identifiants
pubmed: 31638282
doi: 10.1111/1346-8138.15103
pmc: PMC6916343
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1201Subventions
Organisme : Bristol-Myers Squibb
Organisme : ONO Pharmaceutical
Informations de copyright
© 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Clin Cancer Res. 2015 Feb 15;21(4):712-20
pubmed: 25524312
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Asia Pac J Clin Oncol. 2017 Dec;13(6):423-427
pubmed: 28198155
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835